Scroll Back to Top

PD-L1 Quantitative by IHC

CPT 88360
  • PD-L1 Non-specific

Test Details


PD-L1 overexpression is associated with adverse prognosis in solid tumors, though specific prognosis varies among different tumor types. The utility of this PD-L1 (22C3) assay in predicting the response to therapy has not been determined for all tumor types, and standardized scoring methods do not exist for all tumor types.

Special Instructions

Note: This test number is used for tracking oncology IHC specimens to the laboratory. Bill codes will be added when testing is complete, based on the processes performed in the laboratory.


This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.




Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore). 2017 May;96(18):e6369.28471952
Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One. 2015 Jun 26;10(6):e013140.26114883

Specimen Requirements

Information on collection, storage, and volume


Formalin-fixed paraffin-embedded (FFPE) tissue block or slides


One tissue block or five unstained positively charged slides less than one month in age

Minimum Volume

At least three unstained slides sectioned at 4-5 microns


Paraffin block or unstained positive charged slides

Causes for Rejection

Slides sectioned greater than one month prior to test request


Paraffin block or unstained slides sectioned of no more than one month age.